All Programs

Biomarkers Consortium – Treatments Against RA and Effect on FDG PET-CT (TARGET Biomarker Study)

The Problem Rheumatoid arthritis (RA) is currently difficult to treat and people with RA are at increased risk for developing cardiovascula...

Biomarkers Consortium – Mucosal Healing in UC: Definition, Treatment Target and Clinical Endpoints

The Problem Mucosal healing is an important outcome in clinical trials of drugs to treat ulcerative colitis, yet Researchers lack a standar...

Biomarkers Consortium – PROGRESS OA: Clinical Evaluation and Qualification of Osteoarthritis Biomarkers

Overview The Biomarkers Consortium’s PROGRESS OA - Clinical Evaluation and Qualification of Osteoarthritis Biomarkers Project is the seco...

Biomarkers Consortium – Clinical Evaluation and Qualification of Translational Kidney Safety Biomarkers

The Problem When conducting clinical trials of any drugs that could cause acute kidney injury, Researchers need biomarkers that can detect ...

Biomarkers Consortium – Developing Endpoints for Clinical Trials in Community Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Infections (ABSSSI)

The Problem To develop effective treatments for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection...

Accelerating Medicines Partnership® Program – Rheumatoid Arthritis, Systemic Lupus Erythematosus

The Problem Autoimmune disorders such as Rheumatoid Arthritis and Systemic Lupus Erythematosus are biologically complex; understanding the ...

AMP Autoimmune & Immune-Mediated Diseases

The Accelerating Medicines Partnership® (AMP®) Program Autoimmune and Immune-Mediated Diseases (AMP AIM) is a precompetitive partnership t...